Prediction and validation of molecular biological mechanism of Fuzheng Huayu capsule in the treatment of liver cancer

Background:Fuzheng Huayu capsule(FZHY)combined with antiviral treatment has been shown to significantly reduce the risk of liver cancer in patients with hepatitis B cirrhosis.However,the potential of FZHY to directly treat liver cancer remains largely unknown.This study aims to investigate the molecular mechanism underlying the potential of FZHY in treating liver cancer.Methods:A network pharmacological analysis was performed using the Traditional Chinese Medicine Systems Pharmacology database to identify FZHY compounds and targets.Disease targets were searched using the Genecards database,and transcriptome data was downloaded from the NCBI database.Gene Ontology analysis was conducted using the DAVID database,and Kyoto Encyclopedia of Genes and Genomes analysis was based on KOBAS and bioinformatics methods.The Swissdock database was used for molecular docking.In cell experiments,the half inhibitory concentration(IC50)of FZHY was determined using the CCK8 method.The effects of FZHY on cell viability,apoptosis,and mitochondrial membrane potential were evaluated using a fluorescence microscope and flow cytometry.The molecular mechanism of FZHY in treating liver cancer was verified using quantitative polymerase chain reaction.Results:A total of 127 compounds and 184 proteins were identified as potential active ingredients and putative liver cancer-related targets.Additionally,1,899 liver cancer targets,279 transcriptome targets,and 3 pathways(p53 signaling pathway,apoptosis and PI3K-Akt pathway)were collected.The FZHY-targets-liver cancer interaction network was constructed.IC50 of FZHY lyophilized powder solution to liver cancer was 5.13 mg/mL(IC50=5.13 mg/mL).FZHY treatment led to an increase in the ratio of cell apoptosis and induced mitochondrial membrane potential damage,resulting in an increase in the number of dead cells.The expression levels of CCNB1 and BIRC5 were induced with FZHY treatment,while the expression levels of AKR1C3 and IGF2 were reduced.Conclusion:FZHY promotes apoptosis of liver cancer cells by acting on the p53 signaling pathway,apoptosis,and PI3K-Akt pathway.CCNB1,BIRC5,AKR1C3,and IGF2 are potential target proteins for FZHY in treating liver cancer.

Traditional Chinese medicinal capsule for curing HIV/AID Sundergoes clinical test

A traditional Chinese medicinal capsule capable of curing HIV/AIDS has been put under clinical test with the approval of the State Food and Drug Administration.

The effects of Xingnao Jieyu capsules on post-stroke depression are similar to those of fluoxetine

The Xingnao Jieyu capsule has been shown to effectively relieve neurologic impairments and les- sen depression. It remains poorly understood whether this capsule can be used to treat post-stroke depression. Thus, in the present study, we established a rat model of post-stroke depression using left middle cerebral artery occlusions in combination of chronic unpredictable stress and solitary housing during development. Experimental rats received intragastric perfusion with 0.82, 0.41, and 0.20 g/kg Xingnao Jieyu capsules separately dissolved in 2 mL distilled water. Fluoxetine served as a positive control. The treatment was conducted over 28 days. Sugar water consumption test, open-field test, real-time fluorescent quantitative PCR and immunohistochemical staining results demonstrated that intragastric perfusion with various doses of Xingnao Jieyu capsules increased sugar water consumption, voluntary behaviors and synaptotagmin mRNA and protein expression in rats with post-stroke depression. These therapeutic effects were similar to those of fluoxetine. These results indicate that Xingnao Jieyu capsules upregulate synaptotagmin expression in hip pocampi of rats with post-stroke depression, and exert antidepressant effects.

Bushen Yisui Capsule ameliorates axonal injury in experimental autoimmune encephalomyelitis

A preliminary clinical study by our group demonstrated Bushen Yisui Capsule （formerly called Er- huang Formula） in combination with conventional therapy is an effective prescription for the treat- ment of multiple sclerosis. However, its effect on axonal injury during early multiple sclerosis re- mains unclear. In this study, a MOG35 55-immunized C57BL/6 mouse model of experimental auto- immune encephalomyelitis was intragastrically administered Bushen Yisui Capsule. The results showed that Bushen Yisui Capsule effectively improved clinical symptoms and neurological function of experimental autoimmune encephalomyelitis. In addition, amyloid precursor protein expression was down-regulated and microtubule-associated protein 2 was up-regulated. Experimental findings indicate that the disease-preventive mechanism of Bushen Yisui Capsule in experimental autoim- mune encephalomyelitis was mediated by amelioration of axonal damage and promotion of regen- eration. But the effects of the high-dose Bushen Yisui Capsule group was not better than that of the medium-dose and low-dose Bushen Yisui Capsule group in preventing neurological dysfunction.

Influence of Xingnao Jieyu capsule on hippocampal and frontal lobe neuronal growth in a rat model of post-stroke depression

The present study established a rat model of post-stroke depression using incomplete ischemia induced by unilateral carotid artery ligation in combination with solitary raising and subcutaneous injection of a small dose of reserpine. After intragastric perfusion with 45 mg/100 g, 15 mg/100 g, and 7.5 mg/100 g of Xingnao Jieyu for 7, 14 and 21 days, neuronal morphology in the frontal lobe and hippocampus was improved, depression state and voluntary behaviors were also effectively improved in rats with post-stroke depression. Moreover, the effects of Xingnao Jieyu at a dose of 45 and 15 mg/100 g were similar to the traditional antidepressant Prozac.

Study on Effect of Zhixinkang Capsule(脂欣康胶囊)in TreatingUnstable Effort Angina and Hyperlipidemia and Its Function in Vascular Endothelium Protection

Objective:To observe the clinical effect and protection of vascular endothelium of Zhixin-kang Capsule (ZXKC) in middle-aged and old people with unstable effort angina and hyperlipidemia. Methods: Sixty-five patients with unstable effort angina were randomly divided into ZXKC group (34 cases) and control group (31 cases). Conventional western medical therapy was given to both groups, with ZXKC group receiving additional ZXKC treatment. Data of 20 healthy persons were taken as normal group. Forty-eight patients with hyperlipidemia were divided into ZXKC group treated with ZXKC (31 cases) and control group treated with Yixintong (17 cases). The changes of clinical symptoms and laboratory indexes in all the patients were observed before and after treatment. Results: In patients with unstable effort angina, the efficacy of treatment of ZXKC, the withdrawal rate of nitroglycerin, the relieving of symptoms, the improvement of the electrocardiogram, the counts of circulating endothelial cells, the content of platelet P-selectin, the content of plasma endothelin (ET), the activity of superoxide dismutase (SOD) and the activity of malonyldialdehyde (MDA) were all better than those in the control group. In patients with hyperlipidemia, there was no significant difference in lipids reduction between ZXKC group and the control group. In both groups, the total cholesterol (TC), triglyceride (TG), low density lipo-protein-cholesterol (LDL-C), lipoprotein(a) [Lp(a)] , ET, oxidized low density lipoprotein, MDA, arte-riosclerotic index (AI) all lowered obviously, while the SOD, HDL-C and calcitonin gene-related peptide (CGRP) were all elevated markedly. In the ZXKC group, the nitric oxide(NO) increased significantly whereas the ET/CGRP and ET/NO decreased markedly. The total effective rate in symptom relieving, the markedly effective rate, the reduction of TC, ET and ET/CGRP, and the elevation of SOD in ZXKC group were all superior to those in the control group. Conclusion: ZXKC could effectively resist myocardial ischemia, relieve angina, reduce blood lipids, protect vascular endothelial cells, inhibit the activation of platelets, and resist lipid peroxidation.

Mechanism of Erhuang capsule for treatment of multiple sclerosis

Erhuang capsule, a typical formula based on traditional Chinese medicine theory, is widely used to ameliorate multiple sclerosis, inflammation and side effects of glucocortJcoid treatment. Oligodendrocyte precursor cells are neural stem cells that are important for myelin repair and regeneration. In the present study, Erhuang capsule effectively improved clinical symptoms and neurological function scores, reduced mortality and promoted recovery of neurological functions of mice with experimental autoimmune encephalomyelitis. The mechanism of action involved significant increases in oligodendrocyte precursor cell proliferation in specific regions of the brain and spinal cord, increased oligodendrocyte lineage gene 2 expression and enhanced oligodendrocyte precursor cell differentiation.

Modified Cortex Mori Capsules improving the successful rate of functional filtering blebs after reclinical glaucoma filtering surgery

BACKGROUND The major reason for filtering bleb failure or scarring of the bleb site is due to excessive scarring after glaucoma filtration surgery in the clinic.Traditional Chinese medicine has preeminence in the prevention of fibrosis formation through the regulation of systemic circulation and improvement of the properties of the inflammatory cells in the blood.AIM To examine the clinical efficacy of using the Modified Cortex Mori Capsules(MCMC;Chinese name:Jiawei Sangbaipi Capsules)in the success rate of functional filtering blebs after glaucoma filtering surgery in clinical patients.METHODS Sixty resurgery glaucoma patients were randomly divided into two groups:30 patients in surgery with the placebo group and 30 patients in surgery with the MCMC group.Patients took either the placebo or the MCMC 2 wk before and after surgery.Postoperative morphology and function filtering bleb,visual acuity,intraocular pressure,postoperative complications,the success rate of filtration surgery and clinical efficacy were observed.RESULTS Fifty patients completed the study.The percentage of functional filtering blebs in the surgery plus MCMC group was 84%at 6 mo after surgery,which was higher than surgery plus placebo group(64%,P<0.05).The surgical success rate in the MCMC and placebo groups were 79%±8.3%and 57%±10.6%respectively(P<0.05).The visual acuity,intraocular pressure and the postoperative complications in the two groups had no significant differences.CONCLUSION Glaucoma filtering surgery while taking MCMC not only reduced excessive scar formation and increased the success rate of functional filtering blebs but also improved the success of glaucoma filtration operations.

Xiaoyu Jiangzhi capsule protects against heart failure via Ca^(2+)/CaMKII signaling pathways in mice

Objective: Heart failure(HF), a worldwide health condition, is the result of many cardiovascular diseases.The traditional Chinese medicine(TCM) Xiaoyu Jiangzhi capsule(XYC) has long been in use in China to treat hyperlipidemia and inhibit platelet aggregation. This study explores the effects of XYC on heart failure(HF) and its detailed mechanisms.Methods: Isoproterenol(ISO, 30 mg/kg) was injected intraperitoneally for 7 days to copy a HF model of 10-12 weeks old, 20-30 g male mice. We then compared the CON(control) group, ISO(HF model)group, MET(metoprolol) group, and XYC group. Cardiac systolic function and left wall thickness were evaluated by echocardiograph. Using western blot analysis, we detected the proteins of calmodulin dependent protein kinase Ⅱ(Ca MKII) and sarco/endoplasmic reticulum Ca^(2+)-ATPase(Serca). Furthermore, ts A201 cells were cultured and the human CaV1.2 calcium channel current(hCaV1.2) were detected by patch clamp experiments.Results: XYC reduced HF, inhibiting the protein expression of Ca MKII, but Serca did not change significantly. Moreover, XYC inhibited the peak amplitude of the hCaV1.2 current, depolarizing shifted the activation curve 27.6 mV, and shifted the inactivation curve toward a positive potential 17.6 mV. The fraction recovered from inaction was reduced in XYC group compared with that in CON group.Conclusion: XYC could inhibit ISO-induced HF by reducing the Ca^(2+)/Ca MKII signaling pathway in mice.

New insights for infection mechanism and potential targets of COVID-19:Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches

The coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)with high pathogenicity and infectiousness has become a sudden and lethal pandemic worldwide.Currently,there is no accepted specific drug for COVID-19 treatment.Therefore,it is extremely urgent to clarify the pathogenic mechanism and develop effective therapies for patients with COVID-19.According to several reliable reports from China,traditional Chinese medicine(TCM),especially for three Chinese patent medicines and three Chinese medicine formulas,has been demonstrated to effectively alleviate the symptoms of COVID-19 either used alone or in combination with Western medicines.In this review,we systematically summarized and analyzed the pathogenesis of COVID-19,the detailed clinical practice,active ingredients investigation,network pharmacology prediction and underlying mechanism verification of three Chinese patent medicines and three Chinese medicine formulas in the COVID-19 combat.Additionally,we summarized some promising and high-frequency drugs of these prescriptions and discussed their regulatory mechanism,which provides guidance for the development of new drugs against COVID-19.Collectively,by addressing critical challenges,for example,unclear targets and complicated active ingredients of these medicines and formulas,we believe that TCM will represent promising and efficient strategies for curing COVID-19 and related pandemics.

Huayu capsule enhances limb-catching capability of rats with experimental open traumatic brain injury

BACKGROUND： It is hard to cure the open traumatic brain injury （TBI）, especially for the brain functional recovery after brain injury. In this regard, traditional Chinese medicine （TCM） has a wide prospect. OBJECTIVE： To observe the effect of Huayu capsule on limb-catching capability of rat models of open TBI, and investigate its possible mechanism. DESIGN： Randomized and controlled study. SETTING： Grade 3 Pharmacological Laboratory of TCM, State Administration of TCM, Chengdu University of TCM. MATERIALS： This study was performed from October 2005 to January 2006. Fifty Sprague-Dawley rats of either gender, aged 3 months old, weighing from 190 to 220 g, were involved in this study. Huayu capsule was made and supplied by the Department of TCM Processing of Chengdu University of TCM, Lot No. 050121; Xuefuzhuyu oral liquid was manufactured by Jilin Aodong Yanbian Pharmaceutical Industry Co.,Ltd., Lot No. 050406. METHODS： Open right parietal lobe TBI rat models were made as described in references. The involved rat models were randomized into 5 groups according to gender and body mass： model group, high-, middle-, low-dose Huayu capsule groups and Xuefuzhuyu oral liquid group, with 10 rats in each. Rats in the model group were administrated with distilled water of 5 mL/kg; Rats in the high-, middle- and low-dose Huayu capsule groups were administrated with 1.030, 0.515, 0.258 g/kg raw herbs; Rats in the Xuefuzhuyu oral liquid group were administrated with Xuefuzhuyu oral liquid of 5 mL/kg, intragastrically once a day for 7 days successively for all after recovering consciousness from anesthetization. ① One hour after administration on the 6^th day, rats in each group were placed on a 100 cm fine straight iron wire paralleling to the ground and 20 cm above the operational table. The time of the rats keeping on the wire was counted and it indicated the nerve-muscle catching capability. The longer the remained time, the better the nerve-muscle catching capability.② Twenty-four hours after the administration on the 7^th day, the samples of the whole brain were carefully taken out and stained by toluidine blue for observing the morphology of cells in the injured brain tissue. ③ The nerve cells in 4 visual fields from 4 directions （upper, lower, left, right） of injured area of brain tissue were counted. The amount was the total number of the four visual fields. The nerve cells in the injured brain tissue were measured by the same way. ④ On the basis of nerve cell counting, the content of Nissl＇s body in the corresponding nerve cells was measured. MAIN OUTCOME MEASURES： ①Nerve-muscle catching capability. ②Histopathomorphological examination of the injured areas in brain. ③Measurement of nerve cells and macrophages in the injured areas of brain. ④Measurement of content of Nissl＇s body in the injured areas of brain. RESULTS： All the 50 rats were involved in the final analysis. ①The catching time of rats in the high- and middle-dose Huayu capsule groups as well as Xuefuzhuyu oral liquid group was extended to （ 23.6 ± 10.12 ）, （ 18.6 ± 8.17 ） and （22.6 ± 9.43） s, respectively, which was significantly higher than that in the model group [ （12.1 ± 4.15） s, P 〈 0.05 - 0.01 ]. ② The injured areas of brain tissue of rats in the Huayu capsule-treated groups and Xuefuzhuyu oral liquid group were decreased to different extents. The nerve cells adjacent to brain injured area were increased. ③ The number of macrophages around the brain injured area of rats in the high- and middle-dose Huayu capsule groups as well as Xuefuzhuyu oral liquid group was 63.9 ± 7.99, 59.7 ± 7.41 and 62.9 ± 7.37, respectively, which was significantly larger than that in the model group （49.2 ± 8.00, P 〈 0.01 ） . The number of nerve cells adjacent to brain injured area of rats in the high-, middle-, and low-dose Huayu capsule groups as well as Xuefuzhuyu oral liquid group was 86.2 ± 25.93, 93.5 ± 31.79, 92.1 ± 14.54 and 125.2 ±34.25, respectively, which was significantly larger than that in the model group （62.5 ± 16.98, P 〈 0.05 -0.01 ） .④ The total area, the total and integral absorbance, the average gray degree of Nissl＇s body in the cytoplasm of nerve cells of rats in the Huayu capsule-treated groups and Xuefuzhuyu oral liquid group were all significantly increased （P 〈 0.05 - 0.01）. CONCLUSION： Huayu capsule at different doses can promote the limb-catching capability of rat models of open TBI to different extent. This promoting effect may be related to increasing macrophages in the injured area, lessening the apoptosis of nerve cells and increasing the content of Nissl＇s body in the nerve cells.

Fuzheng Huayu Capsule Improves Survival in Patients with HepatitisB-related Cirrhosis and Overt Hepatic Encephalopathy

Objective:Fuzheng Huayu(FZHY)capsules exert anti-liver fibrosis and cirrhosis effects.This study aimed to determine the effect of FZHY on the 6-month survival rate of patients with overt hepatic encephalopathy(OHE)and hepatitis B-related cirrhosis(HBC).Methods:A total of 517 patients with OHE and HBC treated between January 2008 and July 2018 were enrolled.Patients were divided into the FZHY(n=129)and control groups(n=388),and the 6-month survival rates were compared between the two groups.Propensity score matching(PSM)was used to reduce the bias caused by confounding factors.Results:In multivariable regression analysis,FZHY therapy was an independent protective factor of 6-month survival.After PSM(1:2),the FZHY and control group comprised 126 and 252 patients,respectively.The 6-month survival rate was remarkably higher in the FZHY group than in the control group(P<0.005).FZHY users,especially those with a model for end-stage liver disease score>20 and Child-Pugh class C,benefited significantly from FZHY therapy.Conclusions:Adjuvant therapy with FZHY may be associated with improved survival in patients with OHE and HBC.However,further clinical studies are required to validate our findings.

Effects of Longshengzhi Capsules(龙生蛭胶囊)on Parkinson's Disease Based on Network Pharmacology and Biological Research

Objective:To study the effects of Longshengzhi Capsules(龙生蛭胶囊,LSZC)against Parkinson’s disease based on network pharmacology and biological research.Parkinson’s disease(PD)is a kind of degenerative disease with a complex pathological process.Up to date,there is still no effective clinical treatment to cure this condition.The poor prognosis seriously affects patients’quality of life.In the case of dealing with complex pathological processes conditions,the flexible therapy strategy from traditional Chinese medicine(TCM)has unique advantages.LSZC has been clinically approved for the treatment of arteriosclerotic cerebral infarction with symptoms of paraplegia,numbness,skewed mouth,and unfavorable speech.Methods:Active ingredients of LSZC were obtained from TCM systems pharmacology(TCMSP)database,Chinese Taiwan TCM database and Sym Map database.Therapeutic targets were predicted through Pubchem and Swiss Target Prediction databases.Parkinson-related targets were collected by the Comparative Toxicogenomics Database(CTD),TTD and Drug bank databases.The overlap targets of LSZC and PD were identified for pathway enrichment analysis by utilizing Gene Ontology(GO)and the Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis and the Cytoscape software was used to visualize the results.Then the potential pharmacological effects of LSZC on PD were further explored by using mice model induced by MPTP.Results:LSZC showed a regulation effect on the pathological process of PD and improving the symptoms of PD model animals in vivo.And the results also showed that different drug groups have different intervention pathways for PD,suggesting that LSZC intervention on PD may be achieved through multiple channels.Conclusion:LSZC has an intervention effect on the pathological process of PD,indicating that patients with PD may benefit from LSZC usage in clinical practice.

芪蛭益肾胶囊治疗早期糖尿病肾病的多中心前瞻性临床观察

目的:评价芪蛭益肾胶囊治疗糖尿病肾病(DKD)(气阴两虚型)的临床疗效与安全性。方法:采取多中心、区组随机、双盲、安慰剂对照前瞻性研究方法,选取2013年04月—2014年11月全国11所医院478例受试者。采用随机编码表法将患者分为试验组和对照组。试验组口服芪蛭益肾胶囊(1次5粒,1日3次),对照组口服芪蛭益肾胶囊模拟剂(1次5粒,1日3次),共治疗24周,以24 h尿白蛋白排泄率(UAER)作为主要观察指标,并观察24 h尿蛋白定量、肾功能、中医证候评分及不良事件发生情况。结果:治疗后两组UAER均有不同程度下降,但治疗12周、24周后试验组显著低于对照组(P<0.05,P<0.01)。试验组与对照组的UAER下降率在12周末分别为35.81%vs 20.36%(P<0.05),24周后分别为46.08%vs 27.28%(P<0.01),试验组UAER下降率优于对照组。观察结束时试验组UAER较基线下降超过50%的患者比例较对照组多(P<0.05),分别为120(46.51%)vs 30(31.58%)。治疗后试验组24 h尿蛋白定量90.00 mg显著低于对照组131.68 mg(P<0.01)。治疗24周后试验组中医证候疗效为84.5%,显著优于对照组45.26%(P<0.01)。但两组的肾小球滤过率差异无统计学意义(P>0.05),治疗期间两组不良事件发生率差异无统计学意义(P>0.05)。结论:芪蛭益肾胶囊能有效控制DKD(气阴两虚型)尿蛋白,临床使用安全。

金黄膏联合田七祛瘀胶囊治疗胫腓骨骨折术后肿胀临床观察

目的探讨金黄膏联合田七祛瘀胶囊治疗胫腓骨骨折术后肿胀的临床效果。方法以抽样法选取南昌市洪都中医院创伤骨科2022年7月—2022年12月收治的胫腓骨骨折患者60例作为研究对象,根据入组标准,按随机数字表法分为对照组和观察组,每组30例。对照组采用自制中药金黄膏治疗,观察组在对照组的基础上口服田七祛瘀胶囊治疗。治疗后,对两组临床效果进行评估。结果治疗后,观察组患者膝关节疼痛评分低于对照组(P<0.05),两组术后1、3 d肿胀值差异无统计学意义(P>0.05),观察组术后5、7 d肿胀值低于对照组(P<0.05),观察组总有效率96.67%(29/30)高于对照组的73.33%(22/30)(P<0.05)。结论在治疗胫腓骨骨折术后肿胀过程中将内服外敷有效结合,能够取长补短,起到消肿止痛的效果,还能降低疼痛程度,促进患者恢复。

仙灵骨葆胶囊联合唑来膦酸盐及碳酸钙D3片治疗老年骨质疏松症的临床观察

目的探讨仙灵骨葆胶囊联合唑来膦酸盐及碳酸钙D3片对老年骨质疏松症(OP)患者骨转换指标及骨密度的影响。方法选取江西省靖安县人民医院2020年5月—2021年12月收治的老年OP患者94例,随机分为观察组和对照组,各47例。对照组采用唑来膦酸盐联合碳酸钙D3片治疗,观察组在对照组基础上加服仙灵骨葆胶囊治疗,4周为1个疗程。比较2组骨转换指标[骨钙素(OC)、Ⅰ型胶原交联C-末端肽(CTX-1)]、骨密度、骨痛程度[数字疼痛评价量表(NRS)评分]、临床疗效及不良反应。结果治疗后,观察组OC水平高于对照组、CTX-1水平低于对照组,腰椎L_(1~4)、右股骨颈的骨密度高于对照组,NRS评分低于对照组,差异有统计学意义(P<0.05);观察组总有效率95.74%(45/47)高于对照组的80.85%(38/47),差异有统计学意义(P<0.05);2组治疗期间均未见不良反应。结论仙灵骨葆胶囊联合唑来膦酸盐及碳酸钙D_(3)片治疗老年OP效果确切,能改善患者骨转换指标及骨密度,减轻骨痛。

红金消结胶囊联合醋酸亮丙瑞林治疗子宫内膜异位症临床研究

目的:观察红金消结胶囊联合醋酸亮丙瑞林治疗子宫内膜异位症的临床疗效。方法:选取82例子宫内膜异位症患者,按随机数字表法分为对照组与治疗组各41例。对照组给予注射用醋酸亮丙瑞林缓释微球治疗,治疗组在对照组基础上联合红金消结胶囊联合治疗。比较2组临床疗效与不良反应发生率,以及2组治疗前后中医证候评分、血清糖类抗原125 (CA125)、抗子宫内膜抗体(EMAb)、脂联素(APN)、肝细胞生长因子(HGF)水平、子宫体积、子宫内膜厚度、包块直径。结果:治疗组总有效率为95.12%,对照组为78.05%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组中医证候评分均较治疗前降低(P<0.05),且治疗组中医证候评分低于对照组(P<0.05)。治疗后,2组子宫内膜厚度、子宫体积、包块直径均较治疗前缩小(P<0.05),且治疗组上述3项指标均小于对照组(P<0.05)。治疗后,2组血清CA125、EMAb、HGF水平均较治疗前降低(P<0.05),APN水平较治疗前升高(P<0.05);且治疗组CA125、EMAb、HGF水平低于对照组(P<0.05),APN水平高于对照组(P<0.05)。对照组不良反应发生率为9.76%,治疗组为4.88%,2组比较,差异无统计学意义(P>0.05)。结论:红金消结胶囊联合注射用醋酸亮丙瑞林缓释微球治疗子宫内膜异位症疗效显著,能改善患者临床症状和体征,调节相关血清细胞因子水平,且没有增加药物治疗的不良反应。

夏荔芪胶囊联合坦索罗辛治疗前列腺增生症临床疗效观察

目的:观察中药夏荔芪胶囊联合盐酸坦索罗辛缓释胶囊治疗前列腺增生症患者的临床疗效。方法:选取2021年5月8日-2022年11月30日于天津医科大学第二医院收治的前列腺增生患者76例,随机分为试验组和对照组:试验组口服夏荔芪胶囊(1.35 g,3次/d)联合盐酸坦索罗辛缓释胶囊(0.2 mg,每晚睡前服用);对照组仅口服盐酸坦索罗辛缓释胶囊(0.2mg,每晚睡前);两组患者均治疗8周后,比较两组治疗前后国际前列腺症状评分(I-PSS)、中医证候评分、最大尿流率(Qmax)、前列腺体积、残余尿量、NIH-CPSI评分及生活质量评分(QOL),比较两组用药方案的有效性和安全性。结果:治疗后,两组的IPSS评分和中医证候评分与治疗前比较均明显降低(P<0.05),试验组治疗后I-PSS和中医症候评分均小于对照组(P<0.05),其中试验组中医证候评分降低幅度显著大于对照组(P<0.001);治疗后试验组与对照组的前列腺体积、残余尿量及QOL均无统计学差异(P>0.05)。试验组治疗后Qmax大于对照组(P=0.007),且试验组增大幅度显著大于对照组(P<0.001),试验组治疗后NIH-CPSI小于对照组(P=0.044),且试验组治疗前后NIH-CPSI差值大于对照组(P=0.008)。试验组总体有效率达94.7%,大于对照组的42.1%,差异有统计学意义(P<0.001)。结论:夏荔芪胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症的有效性显著高于对照组,且在治疗过程中两组患者均未发生不良事件,安全性与依从性好。

放射损伤的中医药防治及机制

核爆炸、核恐怖袭击以及核电站泄露事故等产生的电离辐射严重威胁公众安全,自日本核废水排海以来,再次引发全球对放射损伤及其防治方案的关注。放射损伤涉及多器官、多组织、多系统,现有药物作用单一、毒副作用大,无法全面有效应对。在整体观指导下的中医药防治方案具有多成分、多途径、多靶点的特色。“早期清热解毒,中期活血化瘀,晚期养血补血”的中医治疗策略可为放射损伤提供全链条的有效应对策略。因此,本文针对外照射导致放射损伤的血虚证、胃肠病、肺病、生殖病的细胞生物学过程,以及介导放射性核素促排的机制,结合其发生发展的中医病机,总结了现代科学对中医药防治放射损伤的解读。同时,以经典抗辐射中药方剂四物汤和刺白胶囊为例,剖析中医药抗辐射的科学内涵,为放射损伤的中医药防治研究提供新视角。

由“虚瘀”理论探讨耆鹿逐痹胶囊防治肾虚血瘀型骨质疏松的作用

骨质疏松症是一种以骨量下降为主要特点的骨代谢性疾病,归属中医“骨痿”范畴,其发病率正逐年上升。常兼见疼痛症状且易引发病理性骨折,让患者深受其折磨。“虚瘀”理论是历代医家所探讨的,有关骨痿的一个重要病机,其核心为肾虚为本,血瘀为标。该文由论述“虚瘀”理论引申至骨痿肾虚血瘀病因病机,进而探讨“补肾活血法”相关治则。同时指出耆鹿逐痹胶囊具有益气养阴,补肾健骨,活血祛风之功效,与“补肾活血法”相符,而且其组成药物所含的有效成分对骨质疏松症也有一定程度的防治作用,从而可以得出耆鹿逐痹胶囊可用于防治肾虚血瘀型骨质疏松症,为临床运用其防治骨质疏松症奠定了一定的基础。